Brainstorm cell therapeutics announces fda advisory committee meeting to review nurown® biologics license application scheduled for september 27, 2023

Pdufa target action date set to occur by december 8, 2023 new york , june 6, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the u.s. food and drug administration (fda) will convene a meeting of the peripheral and central nervous system drugs advisory committee (adcom) to review the biologics license application (bla) for nurown®, its investigational mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (als). the advisory committee meeting has been scheduled for september 27, 2023, and will be available for live streaming.
BCLI Ratings Summary
BCLI Quant Ranking